Increased progesterone receptor expression in uterine leiomyoma Correlation with age number of leiomyomas and clinical symptoms
Progesterone receptor-B mRNA levels in leiomyoma tissue are directly associated with the number of tumors and inversely correlated with the intensity of intermenstrual bleeding and dysmenorrhea.
Anastasia Tsigkou, Ph.D., Fernando M. Reis, M.D., Meng H. Lee, Ph.D., Bingjie Jiang, Ph.D., Claudia Tosti, M.D., Gabriele Centini, M.D., Fang-Rong Shen, M.D., You-Guo Chen, M.D., Felice Petraglia, M.D.
Volume 104, Issue 1, Pages 170–175
To investigate the possible correlation between progesterone receptor (PR) expression in uterine leiomyoma or adjacent myometrium and patient’s age, size/number of leiomyomas, or clinical symptoms such as dysmenorrhea, acyclic pelvic pain, or menstrual and intermenstrual uterine bleeding.
Sixty-two Chinese women undergoing elective hysterectomy for uterine leiomyomata.
Main Outcome Measure(s):
Evaluation of PR-total and PR-B mRNA with real-time polymerase chain reaction; PR-A and PR-B proteins quantified by Western blot in leiomyoma tissue and myometrium; symptoms rated by the patients using visual analog scores.
The PR-B mRNA and PR-A and PR-B proteins were more concentrated in leiomyomas than in matched myometrium. A direct correlation between PR-B mRNA levels in leiomyoma and age (r = 0.347) and number of tumors (r = 0.295) was found. Conversely, there was an inverse correlation between PR-B mRNA levels in leiomyoma and dysmenorrhea (r = −0.260) and intermenstrual bleeding (r = −0.266). Multiple regression analysis indicated that age (β = 0.363) and the number of myomas (β = 0.296) were independently associated with PR-B mRNA levels in leiomyoma tissue.
The levels of PR-B mRNA in leiomyoma tissue are directly associated with the number of tumors and inversely correlated with the intensity of intermenstrual bleeding and dysmenorrhea, suggesting that PR signaling may favor leiomyoma growth while attenuating clinical symptoms. This duality should be taken into account in the clinical management of patients with symptomatic uterine leiomyoma.